Contribution of Chinese Pekin duck complement component C3d-P29 repeats to enhancement of Th2-biased immune responses against NDV F gene induced by DNA immunization

References

• Dempsey, P, Allison, M, Akkaraju, S, Goodnow, C, Fearon, D, 1996. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 271:348–350.
   PubMed Web of Science ®Google Scholar
• Green TD, Montefiori DC, Ross TM. Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d. J Virol 2003;77:2046–2055.
   PubMed Web of Science ®Google Scholar
• Green TD, Newton BR, Rota PA, Xu Y, Robinson HL, Ross TM. C3d enhancement of neutralizing antibodies to measles hemagglutinin. Vaccine 2001; 20:242–248.
   PubMed Web of Science ®Google Scholar
• Li DJ, Wang HM, Li L, Zhao XR, Wang MY, Zhu Y, et al. Gene fusion of molecular adjuvant C3d to hCGβ enhances the anti-hCGβ antibody response in DNA immunization. J Reprod Immunol 2003; 60:129–141.
   PubMed Web of Science ®Google Scholar
• Watanabe I, Ross TM, Tamura S, Ichinohe T, Ito S, Takahashi H, et al. Protection against influenza virus infection by intranasal administration of C3d-fused hemagglutinin. Vaccine 2003; 21:4532–4538.
   PubMed Web of Science ®Google Scholar
• Wang LX, Xu W, Guan QD, Chu YW, Wang Y, Xiong SD. Contribution of C3d-P28 repeats to enhancement of immune responses against HBV-preS2/S induced by gene immunization. World J Gastroenterol 2004; 10(14):2072–2077.
   PubMedGoogle Scholar
• Ross TM, Xu Y, Bright RA, Robinson HL. C3d enhancement of antibodies to Hemagglutinin accelerates protection against influenza virus challenge. Nat Immunol 2000;1:127–131.
   PubMed Web of Science ®Google Scholar
• Mitchell JA, Green TD, Bright RA, Ross TM. Induction of heterosubtypic immunity to influenza A virus using a DNA Vaccine expressing hemagglutinin-C3d fusion proteins. Vaccine 2003;21:902–914.
   PubMed Web of Science ®Google Scholar
• Ross TM, Xu Y, Green TD, Montefiori DC, Robinson HL. Enhanced avidity maturation of antibody to human immunodeficiency virus envelope: DNA vaccination with gp120-C3d fusion proteins. AIDS Res Hum Retroviruses 2001;17:829–835.
   PubMed Web of Science ®Google Scholar
• Firth MA, Moore DP, Pei, YL, Shewen PE, Reggie YC, Lo, DY, et al. 2006. Cloning of a gene fragment encoding bovine complement component C3d with expression and characterization of derived fusion proteins. Veterinary Immunology and Immunopathology.114, 61–71.
   PubMed Web of Science ®Google Scholar
• Ling JY, Liu Z, Tong TZ, Fan HY, Zhang DK, Chen HC, et al. Construction and eukaryotic expression of recombinant plasmid encoding fusion protein of goat complement c3d and foot-and-mouth disease virus vp1. Chin J Biotechnolo2008; 4(2):209–213.
   Google Scholar
• Alexander DJ. Newcastle disease and avian paramyxovirus infections. In: Calnek BW, Barnes HJ, Beard CW, McDougald LR (eds.), Diseases of poultry, 10th ed. Ames: Iowa State University Press, 1997; 541–569.
   Google Scholar
• Bounous DI, Campagnoli RP, Brown J. Comparison of MTT colorimetric assay and tritiated thymidine uptake for lymphocyte proliferation assays using chicken splenocytes, Avian Dis 1992;36:1022–1027.
   PubMed Web of Science ®Google Scholar
• Lambert C, Leonard N, De Bolle X, Depiereux E. ESyPred3D: Prediction of proteins 3D structures J Bioinformat,,; 200218(9):1250∼1256.
   Google Scholar
• Lüthy R, Bowie JU, Eisenberg D. Assessment of protein models with three-dimensional profiles. Nature.1992 Mar 5;356(6364):83–85.
   Google Scholar
• Wiederstein M, Sippl MJ. ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Res2007;35(2):407–410.
   Google Scholar
• Liu XF, Wan HQ, Ni XX, Wu YT, Liu WB (2003) Pathotypical and genotypical characterization of Newcastle disease virus isolated from outbreaks in chicken and goose flocks in some regions of China during 1985–2001. Arch Virol 148: 1387–1403.
   PubMed Web of Science ®Google Scholar
• Liu MA, Wahren B, Karlsson Hedestam GB. DNA vaccines: recent developments and future possibilities. Hum Gene Ther. 2006; 17: 1051–1061.
   PubMed Web of Science ®Google Scholar
• Schalk JA, Mooi FR, Berbers GA, van Aerts LA, Ovelgonne H, Kimman TG. Preclinical and clinical safety studies on DNA vaccines. Hum Vaccine 2006; 2:45–53.
   PubMed Web of Science ®Google Scholar
• Medjitna TD, Stadler C, Bruckner L, Griot C, Ottiger HP. DNA vaccines: safety aspect assessment and regulation. Dev Biol (Basel) 2006;126:261–270; discussion 327.
   PubMedGoogle Scholar
• Fuller DH, Loudon P, Schmaljohn C. Preclinical and clinical progress of particle-mediated DNA vaccines for infectious diseases. Methods 2006;40: 86–97.
   PubMed Web of Science ®Google Scholar
• Donnelly JJ, Ulmer JB, Liu MA. DNA vaccines. Dev Biol Stand 1998;95:43–53.
   PubMedGoogle Scholar
• Robinson HL. DNA vaccines for immunodeficiency viruses. AIDS. 1997;11 (Suppl A ):S109–19.
   PubMedGoogle Scholar
• Robinson HL, Pertmer TM. DNA vaccines for viral infections: basic studies and applications. Adv Virus Res 2000;55:1–74.
   PubMed Web of Science ®Google Scholar
• Test ST, Mitsuyoshi J, Connelly CC, Lucas AH. Increased immunogenicity and induction of class switching by conjugation of complement C3d to pneumococcal serotype 14 capsular polysaccharide. Infect Immun 2001;69: 3031–3040.
   PubMed Web of Science ®Google Scholar
• Suradhat S, Braun RP, Lewis PJ, Babiuk. A, van Drunen Littel-van den Hurk S, Griebel PJ, et al. Fusion of C3d molecule with bovine rotavirus VP7 or bovine herpesvirus type 1 glycoprotein D inhibits immune responses following DNA immunization. Vet Immunol Immunopathol 2001;83:79– 92.
   PubMed Web of Science ®Google Scholar
• Elke S. Bergmann-Leitner WW, Leitner G, Tsokos C. Complement 3d: from molecular adjuvant to target of immune escape mechanisms. Clin Immunol. 2006;121:177—185.
   Google Scholar
• Wang L, Sunyer JO, Bello LJ. Immunogenicity of a bovine viral diarrhea virus E2-C3d fusion protein containing a bovine homolog of C3d. Dev Comp Immuno. 2005;29: 07–915.
   Google Scholar
• Toapanta FR, Ross TM. Mouse strain-dependent differences in enhancement of immune responses by C3d. Vaccine 2004;22:1773–1781.
   PubMed Web of Science ®Google Scholar
• Nagar B, Jones RG, Russell J, et al. X ray crystal structure of C3d: a C3 fragment and ligand for complement receptor 2. Science 1998;280:1277–1280.
   PubMed Web of Science ®Google Scholar
• Fearon DT, Carter RH. The CD19/CR2/TAPA-1 complex of B-lymphocytes: linking natural to acquired immunity. Annu Rev Immunol 1995;13:127–149.
   PubMed Web of Science ®Google Scholar
• Szakonyi G, Guthridge JM, Li D, et al. Structure of complement receptor 2 in complex with its C3d ligand. Science 2001;292:1725–1728.
   PubMedGoogle Scholar
• Rickert RC. Regulation of B lymphocyte activation by complement C3 and the B cell coreceptor complex, Curr Opin Immuno. 2005;17:237–243.
   PubMed Web of Science ®Google Scholar
• Mongini PK, Tolani S, Fattah RJ., Inman JK. Antigen receptor triggered upregulation of CD86 and CD80 in human B cells: augmenting role of the CD21/CD19 co-stimulatory complex and IL-4. Cell Immunol 2002;216:50–64.
   PubMedGoogle Scholar